All News
#eular2020 #op0227 52 wk SEC vs ADA H2H EXCEED trial: Acr20 67.4%SEC vs 61.5%ADA. Better retention of SEC at 85.7% vs 76.3%ADA. SEC significantly outperforms in PASI90 (65.4 SEC be 43.2 ADA) @RheumNow https://t.co/M8UGydTFDF
Olga Petryna DrPetryna ( View Tweet)
#eular2020 #op0314 5 y drug-free remission (5DFR) is rare in early AxSpA: 17%pts from DESIR cohort reach 5DFR. Shorter disease duration (<1.3y), lower BASDAI&ASAS-CRP & less peripheral involv more likely to achieve DFR. Imaging and biological data did not predict DFR @RheumNow
Olga Petryna DrPetryna ( View Tweet)
New genome wide association study on anterior uveitis. Heritability for uveitis is 0.7, much greater than axSpA. Includes great data on genetic risk scores @ARVOiovs @AberdeenEpi @hteraG_senoJ https://t.co/gsX39YfrbN https://t.co/e8qBpL5xwy
Dr Philip Robinson philipcrobinson ( View Tweet)
So maybe the optimal dose for psoriasis with UPA in PsA was tested? UPA works in PsA so another potential Rx for pts LB0001 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/GiT7H91umA
Janet Pope Janetbirdope ( View Tweet)
ENbrel works in long term for the few people left on the drug at 10 yrs with SpA. Enormous dropout. If you are still on Rx for a decade you are in the minority. Drop out of TNFi in SpA mirrors RA & PsA @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/dLS2fw5uRP
Janet Pope Janetbirdope ( View Tweet)
Study in Norway reveals that the majority of the women w/ SpA were not treated with TNF inhibitors before or during pregnancy. Few on TNFi were continued on tx during pregnancy. #EULAR2020 @RheumNow https://t.co/t7B6pASeWQ https://t.co/BwU6RF5Qkn
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Sustained clinical response shown over the 10 yrs of this German study in r-axSpA and nr-axSpA pts treated with ETN. No new safety signals. Abstract #AB0660 #EULAR2020 @RheumNow https://t.co/KCMDyzHaSr https://t.co/yFSTgWqzBQ
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Switching TNFi to VDZ in pts IBD-related SpA associated w/ articular exacerbation of SpA in 1 out of 4 patients within the first 5 months. New-onset MEM is also observed in up to 15% of patients with IBD treated with VDZ. #EULAR2020 @RheumNow https://t.co/ZVjZC7hvxs https://t.co/d1RT3GzB2b
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2020 #op0225 sub study of OPAL Balance: withdrawal of MTxdoes not negatively impact Tofa efficacy in PsA. At 6 mo deltaPASDAS 0.229 (0.079) for tofa mono & 0.q138 (0.081) for tofa+mtx. LFT elevation more common in combination arm @RheumNow https://t.co/NO1agViScD
Olga Petryna DrPetryna ( View Tweet)
Majority are correct. 1/3 of SAPHO meet PsA criteria esp if no osteitis @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/B9wp8JxWpI
Janet Pope Janetbirdope ( View Tweet)
What % of SAPHO pts do you think have PsA? More if synovitis Less if osteitis #EULAR2020 @eular_org @RheumNow @CRASCRRheum AB0038
Janet Pope Janetbirdope ( View Tweet)
#Upadacitinib #psoriaticarthritis Upa works in PsA including imaging and when they show it surprising good PASI scores as well https://t.co/ZWqj8ythHB
Peter Nash drpnash ( View Tweet)
#guselkumab #axialdisease - who would have thunk it - IL23 p19 works in axial involvement PsA with radiology! https://t.co/TaSFBJFRnx
Peter Nash drpnash ( View Tweet)
Filgo reduces PsA markers OP0224. ? Unique to filgo, a JAK1 effect , class effect or part of any effective PsA Rx or some of the above? @eular_org @RheumNow @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/2O5wsLPNl2
Janet Pope Janetbirdope ( View Tweet)
To truly address adherence, you need to understand what is impairing it, and tailor an approach to overcome those barriers.
Great to see this articulated in EULAR recommendations re: non-adherence - a big factor in our therapeutic outcomes!
EULAR projects #EULAR2020 @RheumNow https://t.co/0pazcDFTuV
David Liew drdavidliew ( View Tweet)
ASAS modification of the Berlin algorithm and the duet algorithm for diagnosing axSpA : results from the screening in axSpA for psoriasis, iritis, and colitis cohort: Abstract FRI0298 #EULAR2020 @RheumNow https://t.co/BkG7c2riRb https://t.co/f63MsxWmd3
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Replacing radiographic sacroiliitis with MRI structural damage doesn't change the classifciation of axSpA signifciantly @RheumNow #EULAR2020 Abstract SAT0384 https://t.co/MTTf4fHjYT
Dr Philip Robinson philipcrobinson ( View Tweet)
